ANGPTL3 and renal cell carcinoma: What’s more, PF-562271, an ATP-competitive kinase inhibitor of FAK, did not improve the sensitivity of RCC to sorafenib and did not reverse the resistance caused by ANGPTL3 knockdown (Fig. 5e, f).